Advertisement

Archives of Gynecology and Obstetrics

, Volume 283, Issue 3, pp 651–656 | Cite as

Fertility preservation in >1,000 patients: patient’s characteristics, spectrum, efficacy and risks of applied preservation techniques

  • Barbara Lawrenz
  • Julia Jauckus
  • Markus S. Kupka
  • Thomas Strowitzki
  • Michael von WolffEmail author
Reproductive Medicine

Abstract

Introduction

Data on the characteristics of female patients counselled for fertility preservation and the efficacy and risk of the applied procedures are still poor. We therefore analysed the registry of a network of 70 infertility centers which are involved in fertility preservation in Germany, Switzerland and Austria, called FertiPROTEKT (hhtp://www.fertiprotekt.eu).

Materials and methods

1,280 counselled patients (15–40 years) were analysed regarding characteristics and different fertility preservation treatments before cytotoxic therapy in 2007–2009.

Results

34.8% of the counselled patients were diagnosed with breast cancer, 30.5% with Hodgkin’s lymphoma, 25.4% with other malignancies and 9.3% with non-malignant diseases. 89.6% of the treated breast cancer patients were 25–40 years of age, and 87.5% of the lymphoma patients were 15–30 years of age. At the time of counselling, 85.3% of the breast cancer patients and 92.7% of the lymphoma patients were childless.

1,080 patients received a single or combined therapy such as GnRH agonists (n = 823), cryopreservation of ovarian tissue (n = 500), ovarian stimulation (n = 221) and transposition of the ovaries (n = 24). Only one severe complication, requiring postponement of the chemotherapy, was documented. In stimulated patients, 2,417 oocytes (mean n = 11.6, SD ± 7.7) were received. Fertilisation rate per received oocyte was 61.3%.

Conclusions

Fertility preservation programmes mainly involve women without children, diagnosed with breast cancer or Hodgkin’s lymphoma. Fertility preservation techniques can be applied with low risk. The limited and age-dependant success rate of the different therapies require individualised approaches of single or combined fertility preservation techniques.

Keywords

Fertility preservation IVF Cancer Oocyte GnRH Cryopreservation 

Notes

Acknowledgments

We would like to thank all members of the FertiPROTEKT network for data acquisition. A list of all members is available on the network’s website, under http://www.fertiprotekt.eu. We are greatly indebted to Mrs. Elizabeth Kraemer for reviewing our manuscript.

Conflict of interest

We declare that we have no conflict of interest.

References

  1. 1.
    Schover LR, Rybicke LA, Martin BA, Bringelsen KA (1999) Having children after cancer. A pilot survey of survivors’ attitude and experiences. Cancer 86:697–709CrossRefPubMedGoogle Scholar
  2. 2.
    Schover LR, Brey K, Lichtin A, Lipshultz LI, Jeha S (2002) Knowledge and experience regarding cancer, infertility, and sperm banking in younger male survivors. J Clin Oncol 20:1880–1889CrossRefPubMedGoogle Scholar
  3. 3.
    Quinn GP, Vadaparampil ST, Ji-Hyun L, Jacobsen PB, Bepler G, Lancaster J, Keete DL, Albrecht TL (2009) Physician referral for fertility preservation in oncology patients: a national study of practice behaviors. J Clin Oncol 27:5952–5957CrossRefPubMedGoogle Scholar
  4. 4.
    Beck-Fruchter R, Weiss A, Shalec E (2008) GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: a review of the clinical data. Hum Reprod Update 14(6):553–561CrossRefPubMedGoogle Scholar
  5. 5.
    Blumenfeld Z, von Wolff M (2008) GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy. Hum Reprod Update 14(6):543–552CrossRefPubMedGoogle Scholar
  6. 6.
    Oktay K, Karlikaya G (2000) Ovarian function after transplantation of frozen, banked autologous ovarian tissue. N Engl J Med 342:1919CrossRefPubMedGoogle Scholar
  7. 7.
    Lee SJ, Schover L, Partridge AH, Patrizio P, Wallace W, Hagerty R, Beck LN, Brennan LV, Oktay K (2006) American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 24:2917–2931CrossRefPubMedGoogle Scholar
  8. 8.
    Huober-Zeeb C, Lawrenz B, Popovici R, Strowitzki T, Germeyer A, Stute P, v Wolff M (2010) Improving fertility preservation in cancer: ovarian tissue cryobanking followed by ovarian stimulation can be efficiently combined. Fertil Steril (in press)Google Scholar
  9. 9.
    FertiPROTEKT (2009) Network for fertility preservation before chemo- and radiotherapy. Available at: http://www.fertiprotekt.de/index.php?lang=uk. Accessed 13 November 2009
  10. 10.
    Von Wolff M, Thaler C, Frambach T, Zeeb C, Lawrenz B, Popovici R, Strowitzki T (2009) Ovarian stimulation to crypopreserve fertilized oocytes in cancer patients can be started in the luteal phase. Fertil Steril 92(4):1360–1365CrossRefGoogle Scholar
  11. 11.
    Behringer K, Breuer K, Reineke T, May M, Nogova L, Klimm B, Schmitz T, Wildt L, Diehl V, Engert A, German Hodgkin’s Lymphoma Study Group (2005) Secondary amenorrhea after Hodgkin’s lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 23:7555–7564CrossRefPubMedGoogle Scholar
  12. 12.
    Walshe JM, Denduluri N, Swain S (2006) Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 24:5769–5779CrossRefPubMedGoogle Scholar
  13. 13.
    Bines J, Oleske DM, Cobleigh MA (1996) Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14:1718–1729PubMedGoogle Scholar
  14. 14.
    Klock SC, Zhang JX, Kazer R (2010) Fertility preservation for female cancer patients: early clinical experience. Fertil Steril 94(1):149–155CrossRefPubMedGoogle Scholar
  15. 15.
    Rosendahl M, Andersen CY, Ernst E, Westergaard LG, Rasmussen PE, Loft A, Andersen AN (2008) Ovarian function after removal of an entire ovary for cryopreservation of pieces of cortex prior to gonadotoxic treatment: a follow-up study. Hum Reprod 23(11):2475–2483CrossRefPubMedGoogle Scholar
  16. 16.
    Quintero RB, Helmer A, Huang JQ, Westphal LM (2010) Ovarian stimulation for fertility preservation in patients with cancer. Fertil Steril 93:865–868CrossRefPubMedGoogle Scholar
  17. 17.
    Quintero RB, Helmer A, Murray E, Westphal LM (2005) Fertility preservation in female cancer patients. Fertil Steril 84(1):S70–S71CrossRefGoogle Scholar
  18. 18.
    Oktay K, Sahin G, Ucar KF, Barad D, Blanchette H, Gleicher N (2008) Fertility preservation is an emerging discipline extending beyond cancer patients: Analysis of a large experience. Fertil Steril 90(1):S51CrossRefGoogle Scholar
  19. 19.
    Elassar A, Oktem O, Oktay K (2007) Fertility preservation with ovarian cryopreservation: a decade of experience. Fertil Steril 88(1):S12–S13CrossRefGoogle Scholar
  20. 20.
    Oktay K, Oktem O (2010) Ovarian cryopreservation and transplantation for fertility preservation for medical indications: report of an ongoing experience. Fertil Steril 93:762–768CrossRefPubMedGoogle Scholar
  21. 21.
    Knopmann J, Noyes N, Talebian S, Krey LC, Grifo JA, Licciardi F (2009) Women with cancer undergoing ART for fertility preservation: a cohort study of their response to exogenous gonadotropins. Fertil Steril 91(4):1476–1478CrossRefGoogle Scholar
  22. 22.
    http://www.deutsches-ivf-register.de. Jahrbuch Deutsches IVF-Register 2008
  23. 23.
    Dittrich R, Maltaris T, Hoffmann I, Oppelt PG, Beckmann W, Mueller A (2010) Fertility preservation in cancer patients. Minerva Ginecol 62(1):63–80PubMedGoogle Scholar
  24. 24.
    Von Wolff M, Donnez J, Hovatta O, Keros V, Maltaris T, Montag M, Salle B, Sonmezer M, Andersen CY (2009) Cryopreservation and autotransplantation of human ovarian tissue prior to cytotoxic therapy–A technique in its infancy but already successful in fertility preservation. Eur J Cancer 45(9):1547–1553CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Barbara Lawrenz
    • 1
  • Julia Jauckus
    • 2
  • Markus S. Kupka
    • 3
  • Thomas Strowitzki
    • 2
  • Michael von Wolff
    • 4
    Email author
  1. 1.University Women’s HospitalTübingenGermany
  2. 2.Department of Gynaecological Endocrinology and Reproductive MedicineUniversity Women’s HospitalHeidelbergGermany
  3. 3.University Women’s Hospital, Klinikum MaistrasseMunichGermany
  4. 4.Department of Gynaecological Endocrinology and Reproductive MedicineUniversity Women’s HospitalBernSwitzerland

Personalised recommendations